Piperazinyl-glutamate-pyridines as potent orally bioavailable P2Y12 antagonists for inhibition of platelet aggregation

John J. Parlow, Mary W. Burney, Brenda L. Case, Thomas J. Girard, Kerri A. Hall, Ronald R. Hiebsch, Rita M. Huff, Rhonda M. Lachance, Deborah A. Mischke, Stephen R. Rapp, Rhonda S. Woerndle, Michael D. Ennis

Research output: Contribution to journalArticlepeer-review

21 Scopus citations


Polymer-assisted solution-phase (PASP) parallel library synthesis was used to discover a piperazinyl-glutamate-pyridine as a P2Y12 antagonist. Exploitation of this lead provided compounds with excellent inhibition of platelet aggregation as measured in a human platelet rich plasma (PRP) assay. Pharmacokinetic and physiochemical properties were optimized leading to compound (4S)-4-[({4-[4-(methoxymethyl)piperidin-1-yl]-6-phenylpyridin-2-yl}carbonyl)amino]-5-oxo-5-{4-[(pentyloxy)carbonyl]piperazin-1-yl}pentanoic acid 22J with good human PRP potency, selectivity, in vivo efficacy and oral bioavailability.

Original languageEnglish
Pages (from-to)4657-4663
Number of pages7
JournalBioorganic and Medicinal Chemistry Letters
Issue number16
StatePublished - Aug 15 2009
Externally publishedYes


  • Antiplatelet
  • Antithrombotic
  • Cardiovascular disease
  • GPCR antagonist
  • P2Y12 receptor
  • Polymer-assisted solution-phase

Fingerprint Dive into the research topics of 'Piperazinyl-glutamate-pyridines as potent orally bioavailable P2Y<sub>12</sub> antagonists for inhibition of platelet aggregation'. Together they form a unique fingerprint.

Cite this